PTC Therapeutics presented new data at the 2026 SSIEM Symposium showing Sephience (sepiapterin) significantly lowers blood phenylalanine (Phe) levels and allows greater diet liberalization for patients with phenylketonuria (PKU), including classical PKU cases. Clinical trials and real-world evidence indicate rapid and meaningful Phe reduction, sustained metabolic control, and a favorable safety profile across all patient subgroups. These findings support Sephience's broad potential to improve quality of life for PKU patients by reducing dietary restrictions while maintaining target blood Phe levels. The drug is approved in multiple regions and continues to be studied for its therapeutic benefits.
BrandPilot AI Inc. announced a non-brokered private placement to raise up to $250,000 by issuing 12.5 million units at $0.02 each. Each unit includes one common share and a warrant to buy another share at $0.05 within two years. This follows a previo...
Broadcom projects its AI semiconductor revenue to rise from $56 billion in fiscal 2026 to over $100 billion in fiscal 2027, driven by significant AI financing activities. The company may backstop up to $29 billion in customer lease payments and is re...
The Defiance Daily Target 2X Long RKLB ETF (RKLX) provides leveraged 200% daily exposure to Rocket Lab (RKLB) shares, driven by the company's growth in medium-lift rockets, increasing launch frequency, and an upcoming acquisition of Iridium. This ETF...
In 2026, the SPDR Portfolio S&P 500 High Dividend ETF (SPYD) has seen its quarterly dividend payments increase compared to 2025, while the SPDR Portfolio High Yield Bond ETF (SPHY) has experienced a consistent decline in its monthly distributions. SP...
Eli Lilly has introduced Foundayo, an oral GLP-1 pill for weight loss and type 2 diabetes, in UK pharmacies following recent approval. This tablet offers a convenient alternative to injections and is licensed for adults with certain BMI criteria or w...
